Loading...
Loading...
PKBO| Name | Value |
|---|---|
| Revenues | 0.0 |
| Cost of Revenue | 12.4 |
| Gross Profit | -12.4 |
| Operating Expense | 294.0 |
| Operating I/L | -306.4 |
| Other Income/Expense | -17.5 |
| Interest Income | 0.0 |
| Pretax | -324.0 |
| Income Tax Expense | 0.0 |
| Net Income/Loss | -324.0 |
Peak Bio, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapeutics for oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, is utilized to create a pipeline of novel ADC product candidates to address unmet needs in cancer patients. Their lead product candidate, PHP-303, is a small molecule undergoing Phase II dose clinical study for the orphan disease Alpha1 anti-trypsin deficiency (AATD). Peak Bio, Inc. generates revenue by developing and potentially commercializing these therapeutics to address critical unmet needs in the healthcare market.
